BBIO analyst estimates
BridgeBio Pharma (BBIO) analyst ratings, the average price target and its range, and every firm's latest call.
BBIO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | BridgeBio Pharma price target lowered to $87 from $97 at Morgan Stanley | $87.00 |
| Oct 19, 2026 | Piper Sandler | BridgeBio Pharma price target raised to $120 from $115 at Piper Sandler | $120.00 |
| Oct 15, 2026 | UBS | BridgeBio Pharma assumed with a Buy at UBS | $92.00 |
| Oct 7, 2026 | Barclays | BridgeBio Pharma price target lowered to $156 from $157 at Barclays | $156.00 |
| Sep 1, 2026 | Mizuho Securities | BridgeBio Pharma price target raised to $110 from $96 at Mizuho | $110.00 |
| Aug 12, 2026 | Canaccord Genuity | BridgeBio price target raised to $106 from $104 at Canaccord | $106.00 |
| Aug 12, 2026 | Truist Financial | BridgeBio price target raised to $107 from $102 at Truist | $107.00 |
| Aug 11, 2026 | Piper Sandler | BridgeBio price target raised to $115 from $111 at Piper Sandler | $115.00 |
| Aug 11, 2026 | Wells Fargo | BridgeBio price target raised to $102 from $98 at Wells Fargo | $102.00 |
| Aug 11, 2026 | Morgan Stanley | BridgeBio price target lowered to $97 from $98 at Morgan Stanley | $97.00 |
| Aug 11, 2026 | Cantor Fitzgerald | Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO), Updates Estimates | $110.00 |
| Jul 13, 2026 | H.C. Wainwright | BridgeBio price target raised to $120 from $110 at H.C. Wainwright | $120.00 |
| Jun 16, 2026 | Mizuho Securities | BridgeBio Pharma (BBIO) PT Lowered to $96 at Mizuho | $96.00 |
| Jun 3, 2026 | Canaccord Genuity | BridgeBio initiated with a Buy at Canaccord | $104.00 |
| May 28, 2026 | Morgan Stanley | BridgeBio price target raised to $98 from $94 at Morgan Stanley | $98.00 |
- 19 firms rate BBIO: 17 buy, 2 hold, 0 sell.
- The average price target is $111.00 from 10 analysts, from $87.00 to $156.00.
Updated 2026-11-02 17:54 UTC